| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.EJCA.2007.07.031 |
| P698 | PubMed publication ID | 17845846 |
| P50 | author | Giuseppe Giaccone | Q37829946 |
| P2093 | author name string | Christopher M Booth | |
| A Hilary Calvert | |||
| Elizabeth A Eisenhauer | |||
| Lesley K Seymour | |||
| Marinus W Lobbezoo | |||
| P433 | issue | 1 | |
| P304 | page(s) | 25-29 | |
| P577 | publication date | 2007-09-12 | |
| P1433 | published in | European Journal of Cancer | Q332260 |
| P1476 | title | Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT) | |
| P478 | volume | 44 |
| Q92890383 | A Review of Perspectives on the Use of Randomization in Phase II Oncology Trials |
| Q34587714 | A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). |
| Q38045514 | A theoretical framework for early human studies: uncertainty, intervention ensembles, and boundaries |
| Q33561602 | Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial |
| Q54569640 | Adjuvant Trials of Targeted Agents: The Newest Battleground in the War on Cancer |
| Q35565672 | Advances in Statistical Approaches Oncology Drug Development |
| Q34032803 | Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center |
| Q37132809 | Clinical trial design for testing the stem cell model for the prevention and treatment of cancer |
| Q37325089 | Comparison of power between randomized discontinuation design and upfront randomization design on progression-free survival. |
| Q33433456 | Current issues in oncology drug development, with a focus on Phase II trials |
| Q39463857 | Design and conduct of early clinical studies of two or more targeted anticancer therapies: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies |
| Q33945307 | Designing phase II trials in cancer: a systematic review and guidance |
| Q33870594 | Effective incorporation of biomarkers into phase II trials |
| Q37822199 | Making the Investigational Oncology Pipeline More Efficient and Effective: Are We Headed in the Right Direction? |
| Q37152009 | Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. |
| Q90056572 | Objective response rate assessment in oncology: Current situation and future expectations |
| Q44786644 | Performance of multinomial designs in comparison with response-based designs in non-randomized phase II trials of targeted cancer agents |
| Q34941964 | Phase 0 clinical trials in oncology new drug development |
| Q33985780 | Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies |
| Q47163554 | Quality of reporting in oncology phase II trials: A 5-year assessment through systematic review |
| Q53083460 | Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials |
| Q37232368 | Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives |
| Q37173942 | Randomized phase II designs. |
| Q43140987 | Recommended changes to oncology clinical trial design: revolution or evolution? |
| Q36509433 | The Italian Network for Tumor Biotherapy (NIBIT): getting together to push the field forward. |
| Q33732581 | The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee |
Search more.